Ablynx Nv (ABLYF) 12.1000 $ABLYF
Global Lung Disease Pipeline Review Report 2014
M2 - Tue Apr 15, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9dvt9/lung_disease) has announced the addition of the "Lung Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Lung Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lung Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lung Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Lung Disease - Companies Involved in Therapeutics Development - Ablynx NV - Vectura Group plc - Pharmaxis Limited - AGI Therapeutics plc - Nostrum Pharmaceuticals, LLC - PharmaIN Corporation - Paranta Biosciences Limited - Serendex Pharmaceuticals A/S Drug Profiles - cladribine - sargramostim - VR-461 - PXS-4206 - AGI-350 - dapsone - Retinoic Acid Receptor Agonists - Recombinant Human Follistatin - PGC-VIP - Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Lung And Liver Diseases - Nanobody 1 For Pulmonary Disease - Nanobody 2 For Pulmonary Disease - Ornithine-Substituted ADP-Ribosyl HNP-1 - Ornithine-HNP-1 For more information visit http://www.researchandmarkets.com/research/v9...ng_disease
What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer
Marketwire - Mon Aug 19, 12:27AM CDT
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team. In this newly created role, Dr Menrad will be responsible for developing and executing the Company's research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team. Dr Menrad will report directly to Andrew Kay, Algeta's President & CEO, and takes up his position immediately.
ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY
Thomson Reuters ONE - Thu Jul 18, 3:11AM CDT
Activaero GmbH / ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY . Ad hoc announcement according to 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major Shareholdings (the "Transparency Law"
Marketwire - Fri Mar 08, 11:45AM CST
Ablynx (EURONEXT BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies(R), announces today that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO" took place on 5 March 2013 and as a result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares were issued that same day as a result of the exercise of 641,800 warrants.
Global Lung Disease Pipeline Review Report 2014
M2 - Tue Apr 15, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9dvt9/lung_disease) has announced the addition of the "Lung Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Lung Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lung Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lung Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Lung Disease - Companies Involved in Therapeutics Development - Ablynx NV - Vectura Group plc - Pharmaxis Limited - AGI Therapeutics plc - Nostrum Pharmaceuticals, LLC - PharmaIN Corporation - Paranta Biosciences Limited - Serendex Pharmaceuticals A/S Drug Profiles - cladribine - sargramostim - VR-461 - PXS-4206 - AGI-350 - dapsone - Retinoic Acid Receptor Agonists - Recombinant Human Follistatin - PGC-VIP - Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Lung And Liver Diseases - Nanobody 1 For Pulmonary Disease - Nanobody 2 For Pulmonary Disease - Ornithine-Substituted ADP-Ribosyl HNP-1 - Ornithine-HNP-1 For more information visit http://www.researchandmarkets.com/research/v9...ng_disease
What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer
Marketwire - Mon Aug 19, 12:27AM CDT
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team. In this newly created role, Dr Menrad will be responsible for developing and executing the Company's research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team. Dr Menrad will report directly to Andrew Kay, Algeta's President & CEO, and takes up his position immediately.
ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY
Thomson Reuters ONE - Thu Jul 18, 3:11AM CDT
Activaero GmbH / ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY . Ad hoc announcement according to 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major Shareholdings (the "Transparency Law"
Marketwire - Fri Mar 08, 11:45AM CST
Ablynx (EURONEXT BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies(R), announces today that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"
took place on 5 March 2013 and as a result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares were issued that same day as a result of the exercise of 641,800 warrants. 
